- Report
- October 2024
- 184 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 88 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- September 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- May 2024
- 80 Pages
United States
From €3755EUR$3,950USD£3,155GBP
- Report
- May 2024
- 140 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- May 2021
- 174 Pages
Global
From €1307EUR$1,375USD£1,098GBP
€2614EUR$2,750USD£2,196GBP
- Report
- December 2022
- 180 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- August 2023
- 74 Pages
Egypt
From €3327EUR$3,500USD£2,795GBP
- Report
- April 2022
- 181 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- October 2023
- 146 Pages
Global
From €3353EUR$3,528USD£2,817GBP
€3945EUR$4,150USD£3,314GBP
- Report
- July 2024
- 84 Pages
Global
From €3500EUR$3,944USD£3,043GBP
The Liver Cancer Diagnostics market is a subset of the larger Diagnostics industry. It is focused on the development and commercialization of tests and technologies used to detect and diagnose liver cancer. These tests can include imaging techniques such as ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI). Additionally, blood tests, biopsies, and other laboratory tests may be used to diagnose liver cancer.
The Liver Cancer Diagnostics market is highly competitive, with a range of companies offering products and services. These include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Becton Dickinson, and Hologic. Other companies in the market include Agilent Technologies, Bio-Rad Laboratories, and Cepheid. Show Less Read more
